{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Breast+Carcinoma&page=18", "query": { "condition": "Metastatic Breast Carcinoma", "page": 18 }, "page_size": 10 }, "pagination": { "page": 18, "page_size": 10, "total_count": 2114, "total_pages": 212, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Breast+Carcinoma&page=19&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Breast+Carcinoma&page=17&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T05:21:16.200Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00003403", "title": "GPX-100 in Treating Patients With Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "GPX-100", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gem Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1999-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-04-23", "last_synced_at": "2026-10-15T05:21:16.200Z", "location_count": 2, "location_summary": "Jacksonville, Florida • Salt Lake City, Utah", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003403" }, { "nct_id": "NCT02834013", "title": "Nivolumab and Ipilimumab in Treating Patients With Rare Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acinar Cell Carcinoma", "Adenoid Cystic Carcinoma", "Adrenal Cortical Carcinoma", "Adrenal Gland Pheochromocytoma", "Anal Canal Neuroendocrine Carcinoma", "Anal Canal Undifferentiated Carcinoma", "Angiosarcoma", "Apocrine Neoplasm", "Appendix Mucinous Adenocarcinoma", "Bartholin Gland Transitional Cell Carcinoma", "Basal Cell Carcinoma", "Bladder Adenocarcinoma", "Breast Metaplastic Carcinoma", "Cervical Adenocarcinoma", "Cholangiocarcinoma", "Chordoma", "Colorectal Squamous Cell Carcinoma", "Desmoid Fibromatosis", "Endometrial Transitional Cell Carcinoma", "Endometrioid Adenocarcinoma", "Esophageal Neuroendocrine Carcinoma", "Esophageal Undifferentiated Carcinoma", "Extrahepatic Bile Duct Carcinoma", "Extramammary Paget Disease", "Fallopian Tube Adenocarcinoma", "Fallopian Tube Transitional Cell Carcinoma", "Fibromyxoid Tumor", "Gallbladder Carcinoma", "Gastric Neuroendocrine Carcinoma", "Gastric Squamous Cell Carcinoma", "Gastric Undifferentiated Carcinoma", "Gastrointestinal Stromal Tumor", "Gestational Trophoblastic Tumor", "Giant Cell Carcinoma", "Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type", "Intestinal Neuroendocrine Carcinoma", "Intrahepatic Cholangiocarcinoma", "Lung Neuroendocrine Tumor", "Lung Sarcomatoid Carcinoma", "Major Salivary Gland Carcinoma", "Malignant Neoplasm of Unknown Primary", "Malignant Odontogenic Neoplasm", "Malignant Peripheral Nerve Sheath Tumor", "Malignant Solid Neoplasm", "Malignant Testicular Sex Cord-Stromal Tumor", "Metastatic Pituitary Neuroendocrine Tumor", "Minimally Invasive Lung Adenocarcinoma", "Mixed Mesodermal (Mullerian) Tumor", "Mucinous Adenocarcinoma", "Mucinous Cystadenocarcinoma", "Nasal Cavity Adenocarcinoma", "Nasal Cavity Carcinoma", "Nasopharyngeal Carcinoma", "Nasopharyngeal Low Grade Papillary Adenocarcinoma", "Nasopharyngeal Undifferentiated Carcinoma", "Oral Cavity Carcinoma", "Oropharyngeal Undifferentiated Carcinoma", "Ovarian Adenocarcinoma", "Ovarian Germ Cell Tumor", "Ovarian Mucinous Adenocarcinoma", "Ovarian Squamous Cell Carcinoma", "Ovarian Transitional Cell Carcinoma", "Pancreatic Acinar Cell Carcinoma", "Pancreatic Neuroendocrine Carcinoma", "Paraganglioma", "Paranasal Sinus Adenocarcinoma", "Paranasal Sinus Carcinoma", "Parathyroid Gland Carcinoma", "PEComa", "Penile Squamous Cell Carcinoma", "Peritoneal Mesothelial Neoplasm", "Placental Choriocarcinoma", "Primary Peritoneal High Grade Serous Adenocarcinoma", "Pseudomyxoma Peritonei", "Rare Disorder", "Scrotal Squamous Cell Carcinoma", "Seminal Vesicle Adenocarcinoma", "Seminoma", "Serous Cystadenocarcinoma", "Small Intestinal Adenocarcinoma", "Small Intestinal Squamous Cell Carcinoma", "Spindle Cell Neoplasm", "Teratoma With Somatic-Type Malignancy", "Testicular Non-Seminomatous Germ Cell Tumor", "Thyroid Gland Carcinoma", "Tracheal Carcinoma", "Transitional Cell Carcinoma", "Ureter Adenocarcinoma", "Ureter Squamous Cell Carcinoma", "Urethral Adenocarcinoma", "Urethral Squamous Cell Carcinoma", "Vaginal Adenocarcinoma", "Vaginal Squamous Cell Carcinoma, Not Otherwise Specified", "Vulvar Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 798, "start_date": "2017-01-30", "completion_date": "2027-06-01", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-10-15T05:21:16.200Z", "location_count": 1006, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 620 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02834013" }, { "nct_id": "NCT07706179", "title": "Targeting Aurora A Kinase to Overcome Treatment Resistance in Advanced HR+/HER2+ Breast Cancer", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HR+/HER2+ Breast Cancer", "Metastatic Breast Cancer" ], "interventions": [ { "name": "Alisertib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2026-10", "completion_date": "2028-09", "has_results": false, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-15T05:21:16.200Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT07706179" }, { "nct_id": "NCT00051779", "title": "An Investigational Drug (CAL) Versus Zoledronic Acid (Zometa®) in Patients With Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Neoplasms", "Breast Cancer", "Metastasis" ], "interventions": [ { "name": "CAL", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Chugai Pharma USA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-10-15T05:21:16.200Z", "location_count": 38, "location_summary": "Little Rock, Arkansas • Springdale, Arkansas • Concord, California + 32 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Concord", "state": "California" }, { "city": "Greenbrae", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00051779" }, { "nct_id": "NCT00028496", "title": "Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adenocarcinoma of the Colon", "Adenocarcinoma of the Gallbladder", "Adenocarcinoma of the Pancreas", "Adenocarcinoma of the Rectum", "Adult Primary Hepatocellular Carcinoma", "Advanced Adult Primary Liver Cancer", "Cholangiocarcinoma of the Gallbladder", "Diffuse Adenocarcinoma of the Stomach", "Intestinal Adenocarcinoma of the Stomach", "Male Breast Cancer", "Mixed Adenocarcinoma of the Stomach", "Ovarian Endometrioid Adenocarcinoma", "Paget Disease of the Breast With Intraductal Carcinoma", "Paget Disease of the Breast With Invasive Ductal Carcinoma", "Recurrent Adult Primary Liver Cancer", "Recurrent Breast Cancer", "Recurrent Colon Cancer", "Recurrent Gallbladder Cancer", "Recurrent Gastric Cancer", "Recurrent Malignant Testicular Germ Cell Tumor", "Recurrent Pancreatic Cancer", "Recurrent Rectal Cancer", "Recurrent Salivary Gland Cancer", "Salivary Gland Adenocarcinoma", "Stage II Malignant Testicular Germ Cell Tumor", "Stage II Pancreatic Cancer", "Stage III Colon Cancer", "Stage III Gastric Cancer", "Stage III Malignant Testicular Germ Cell Tumor", "Stage III Pancreatic Cancer", "Stage III Rectal Cancer", "Stage III Salivary Gland Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IV Breast Cancer", "Stage IV Colon Cancer", "Stage IV Gastric Cancer", "Stage IV Pancreatic Cancer", "Stage IV Rectal Cancer", "Stage IV Salivary Gland Cancer", "Thyroid Gland Medullary Carcinoma", "Unresectable Gallbladder Cancer" ], "interventions": [ { "name": "recombinant fowlpox-CEA(6D)/TRICOM vaccine", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "recombinant fowlpox GM-CSF vaccine adjuvant", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2001-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-25", "last_synced_at": "2026-10-15T05:21:16.200Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00028496" }, { "nct_id": "NCT00437073", "title": "Brain Metastases In ErbB2-Positive Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasms, Breast" ], "interventions": [ { "name": "capecitabine", "type": "DRUG" }, { "name": "topotecan", "type": "DRUG" }, { "name": "lapatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2007-05", "completion_date": "2010-02", "has_results": true, "last_update_posted_date": "2015-10-15", "last_synced_at": "2026-10-15T05:21:16.200Z", "location_count": 13, "location_summary": "Washington D.C., District of Columbia • Indianapolis, Indiana • Sioux City, Iowa + 10 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Sioux City", "state": "Iowa" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00437073" }, { "nct_id": "NCT01269346", "title": "Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Eribulin Mesylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 52, "start_date": "2010-12", "completion_date": "2016-05", "has_results": true, "last_update_posted_date": "2023-06-22", "last_synced_at": "2026-10-15T05:21:16.200Z", "location_count": 26, "location_summary": "Denver, Colorado • Davie, Florida • Jacksonville, Florida + 22 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Davie", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Ocala", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01269346" }, { "nct_id": "NCT02971761", "title": "Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Androgen Receptor Positive", "Estrogen Receptor Negative", "HER2/Neu Negative", "Metastatic Triple-Negative Breast Carcinoma", "Progesterone Receptor Negative", "Stage IV Breast Cancer AJCC v6 and v7" ], "interventions": [ { "name": "Enobosarm", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2017-06-01", "completion_date": "2022-08-16", "has_results": true, "last_update_posted_date": "2024-02-20", "last_synced_at": "2026-10-15T05:21:16.200Z", "location_count": 7, "location_summary": "Corona, California • Duarte, California • Lancaster, California + 4 more", "locations": [ { "city": "Corona", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Lancaster", "state": "California" }, { "city": "Mission Hills", "state": "California" }, { "city": "Rancho Cucamonga", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02971761" }, { "nct_id": "NCT06525766", "title": "Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "Estrogen-receptor-positive Breast Cancer", "Metastatic HER2-Negative Breast Carcinoma", "Metastatic Breast Cancer" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2025-10-01", "completion_date": "2030-10-15", "has_results": false, "last_update_posted_date": "2026-08-12", "last_synced_at": "2026-10-15T05:21:16.200Z", "location_count": 1, "location_summary": "Scottsdale, Arizona", "locations": [ { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06525766" }, { "nct_id": "NCT01234337", "title": "Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Sorafenib (Nexavar, BAY43-9006)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 537, "start_date": "2011-02-21", "completion_date": "2017-10-20", "has_results": true, "last_update_posted_date": "2018-11-06", "last_synced_at": "2026-10-15T05:21:16.200Z", "location_count": 19, "location_summary": "Greenbrae, California • Sylmar, California • West Palm Beach, Florida + 15 more", "locations": [ { "city": "Greenbrae", "state": "California" }, { "city": "Sylmar", "state": "California" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "Joliet", "state": "Illinois" }, { "city": "Evansville", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01234337" } ] }